Rua launches product into Czechia in major EU milestone

1
st
September 2025


FOR PUBLIC RELEASE

Rua Bioscience launches product into Czechia in major European milestone
Rua Bioscience (NZX: RUA) is pleased to announce the successful launch of its first medicinal
cannabis product in Czechia, marking a significant step forward in Rua’s strategy to expand its
European footprint. The launch comes in partnership with Motagon s.r.o., a leading Czech-based
pharmaceutical distributor with whom Rua has entered a formal distribution agreement for
Czechia, Poland and other eastern European countries.
Strengthening our presence in Europe
This expansion is the latest execution of Rua’s international growth strategy, targeting high-
value markets where demand for medicinal cannabis is accelerating. Czechia presents a
compelling opportunity. Following regulatory reforms in April 2025, General Practitioners are
now permitted to prescribe medicinal cannabis, a shift that is expected to significantly grow
patient access and market size.
CEO Paul Naske said, "Our launch into Czechia is more than a commercial achievement – it’s a
demonstration of Rua’s regulatory experience and relationships to strategically enter growing
international markets as the medicinal cannabis landscape evolves. This move builds on our
success in Germany and strengthens Rua’s footprint in Europe."
Partnering with Motagon for trusted distribution
Motagon brings deep expertise in the Czech medicinal cannabis sector and a well-established
distribution network. With their strong regulatory understanding, sales and marketing team and
relationships with healthcare providers and pharmacies, Motagon is ideally placed to ensure
Rua products are accessible to Czech patients from day one.
A growing market with exciting potential
The Czech medicinal cannabis market, although still emerging, is forecast to expand
significantly due to the recent regulatory changes. In 2025, approximately 4,000 patients are
prescribed cannabis-based treatments monthly, with analysts projecting this number could
double within two years. Rua believes this presents a strong foundation for growth.

Aligned with Rua’s mission and purpose
This milestone reflects Rua Bioscience’s founding kaupapa – to distribute high-value medicinal
cannabis products that change lives. Each market Rua enters is a step toward fulfilling this
vision, building commercial success on a foundation of purpose and partnership.
Rua will continue to monitor the Czech market closely, with additional product launches planned
as demand grows.

For more information go to www.ruabio.com/investors


ENDS

The person who authorised this statement:
Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154

17
67
109
157
210
319
201920202021202220232024
Weight of cannabis products prescribed (kg)
(Czechia Ministry of Health)

1
st
September 2025



KUA MUTU


Te tangata nana i whakamana i tenei panui:
Paul Naske
Chief Executive Officer
paul.naske@ruabio.com

+64 21 445154